AIBioTech Announces a New Test to Assess L-asparaginase Levels in Patients Undergoing Treatment for Acute Lymphoblastic Leukemia

Published: Feb 05, 2013

RICHMOND, Va.--(BUSINESS WIRE)--AIBioTech™ is pleased to announce implementation of a new laboratory derived test to measure L-asparaginase levels in patients being treated with any of the current asparaginase drugs including: Oncaspar®, Kidrolase®, Erwinaze™, and Elspar®. About 5,500 new cases of pediatric acute lymphoblastic leukemia (ALL) are diagnosed in the United States each year. Unlike healthy cells, leukemia cells cannot make their own supply of asparagine, an essential amino acid nutrient, and are dependent on obtaining asparagine from a leukemia patient’s blood serum.

Back to news